Pentoxifylline - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pentoxifylline and what is the scope of freedom to operate?
Pentoxifylline
is the generic ingredient in three branded drugs marketed by Ani Pharms, Apotex, Heritage Pharms, Impax Labs, Pliva, Rising, Valeant Pharms, Upsher Smith Labs, and Validus Pharms, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for pentoxifylline. Nine suppliers are listed for this compound.
Summary for pentoxifylline
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 9 |
| NDAs: | 11 |
| Drug Master File Entries: | 14 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 157 |
| Patent Applications: | 6,965 |
| Drug Prices: | Drug price trends for pentoxifylline |
| What excipients (inactive ingredients) are in pentoxifylline? | pentoxifylline excipients list |
| DailyMed Link: | pentoxifylline at DailyMed |
Recent Clinical Trials for pentoxifylline
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sunnybrook Health Sciences Centre | Phase 3 |
| Tata Memorial Centre | Phase 2 |
| Bhabha Atomic Research Centre (BARC) | Phase 2 |
Pharmacology for pentoxifylline
| Drug Class | Blood Viscosity Reducer |
| Physiological Effect | Hematologic Activity Alteration |
Medical Subject Heading (MeSH) Categories for pentoxifylline
Anatomical Therapeutic Chemical (ATC) Classes for pentoxifylline
US Patents and Regulatory Information for pentoxifylline
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 075028-001 | Jul 20, 1998 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rising | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 074425-001 | Jul 8, 1997 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ani Pharms | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 075107-001 | Sep 4, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Impax Labs | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 075093-001 | Aug 10, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pliva | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 074874-001 | May 25, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ani Pharms | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 075199-001 | Sep 3, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for pentoxifylline
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
